Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HYDRO-RESERP vs ALDORIL D50
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing reabsorption of sodium and chloride and promoting diuresis. Reserpine is a Rauwolfia alkaloid that depletes catecholamines (norepinephrine, dopamine, serotonin) from adrenergic nerve endings and brain, leading to reduced sympathetic outflow and vasodilation.
Aldoril D50 is a combination of methyldopa and hydrochlorothiazide. Methyldopa is a centrally-acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume and further lowering blood pressure.
Hypertension
Hypertension (first-line or second-line therapy),Hypertensive urgency (off-label)
HYDRO-RESERP contains hydrochlorothiazide (HCTZ) and reserpine. HCTZ: 25-100 mg daily orally; reserpine: 0.125-0.25 mg daily orally. Administer once daily unless intolerable hypotension; then split doses. Avoid doses exceeding HCTZ 100 mg/day and reserpine 0.25 mg/day.
1 tablet (hydrochlorothiazide 25 mg + methyldopa 250 mg) orally twice daily; maximum dose: 2 tablets (50 mg + 500 mg) twice daily.
50-100 hours (terminal); prolonged in renal impairment, leading to accumulation on repeated dosing.
3–6 hours (terminal elimination half-life); clinical context: requires twice-daily dosing for sustained blood pressure control; prolonged in renal impairment.
Hydrochlorothiazide is not extensively metabolized; it is excreted unchanged in urine. Reserpine is extensively metabolized in the liver by hydrolysis and conjugation.
Methyldopa is extensively metabolized in the liver via conjugation and O-methylation, with involvement of catechol-O-methyltransferase (COMT). Hydrochlorothiazide is not extensively metabolized; it is eliminated largely unchanged by the kidneys.
Renal: 30-40% as unchanged reserpine; biliary/fecal: 60-70% as metabolites.
Renal: 50% as unchanged drug and 20% as metabolites; biliary/fecal: ~25% (as metabolites); total renal clearance accounts for ~70% of elimination.
96% bound to albumin and alpha1-acid glycoprotein.
~20% bound to albumin; minimal binding to other plasma proteins.
1.5-2.5 L/kg; extensive tissue distribution with high affinity for adrenergic neurons.
0.2–0.3 L/kg (moderately low Vd, indicating limited extravascular distribution and predominantly plasma water distribution).
Oral: 50-60% (first-pass metabolism); IM: ~100%.
Oral: 30–40% (due to extensive first-pass metabolism); IV: 100%.
Contraindicated if e GFR <30 m L/min/1.73m² due to HCTZ ineffectiveness. For GFR 30-50 m L/min: reduce HCTZ to 12.5-25 mg daily; reserpine unchanged. Monitor serum creatinine and electrolytes. Not recommended for anuric patients.
Contraindicated if GFR < 30 m L/min; for GFR 30-50 m L/min: reduce dose and monitor electrolytes.
Child-Pugh A: no adjustment. Child-Pugh B: reduce HCTZ by 25-50% (start at 12.5 mg) due to risk of electrolyte imbalance; reserpine: use lowest effective dose (0.125 mg) and monitor for encephalopathy. Child-Pugh C: avoid HCTZ; reserpine contraindicated due to risk of hepatic coma.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50% and monitor; Class C: contraindicated.
Not approved for pediatric use. Limited data: HCTZ 1-2 mg/kg/day orally once or divided; max 50 mg/day. Reserpine 0.01-0.02 mg/kg/day in 1-2 doses; max 0.25 mg/day. Monitor growth, electrolytes, and blood pressure closely in children.
Not recommended; inadequate safety data.
Start at half the adult dose: HCTZ 12.5 mg orally daily; reserpine 0.05-0.1 mg daily. Titrate slowly (every 2-4 weeks). Monitor for orthostatic hypotension, electrolyte disturbances, depression (reserpine), and dehydration. Avoid in frail elderly due to increased fall risk.
Start with 1 tablet (hydrochlorothiazide 12.5 mg + methyldopa 125 mg) once daily; increase slowly; monitor for hypotension and electrolyte imbalance.
Reserpine may cause mental depression, especially in patients with a history of depression. Risks are dose-related and may persist after discontinuation. Use with caution or avoid in patients with a history of depression.
None
May cause depression with suicidal risk (reserpine).,May cause electrolyte imbalances (hypokalemia, hyponatremia) due to hydrochlorothiazide.,May increase serum uric acid and precipitate gout.,May cause orthostatic hypotension and bradycardia.,Use cautiously in patients with renal impairment or hepatic disease.
Sedation and drowsiness common; avoid driving or hazardous activities. Risk of Coombs-positive hemolytic anemia with methyldopa (discontinue if anemia develops). Hepatotoxicity and liver function abnormalities (discontinue if jaundice occurs). Orthostatic hypotension; caution in volume-depleted patients. Electrolyte imbalances (particularly hypokalemia, hyponatremia) with hydrochlorothiazide; monitor serum electrolytes. Sulfonamide cross-sensitivity possible. Exacerbation of systemic lupus erythematosus. Avoid abrupt withdrawal of methyldopa (may cause rebound hypertension).
Hypersensitivity to hydrochlorothiazide, reserpine, or sulfonamide derivatives.,History of depression (especially with reserpine).,Active peptic ulcer or ulcerative colitis (reserpine).,Electroconvulsive therapy (within 1 week).,Severe renal impairment (anuria) or severe hepatic disease.,Pregnancy (especially in second and third trimesters; avoid use).
Active hepatic disease (cirrhosis, hepatitis) associated with methyldopa therapy; previous methyldopa-induced liver disorders. Anuria or hypersensitivity to thiazide diuretics or sulfonamide-derived drugs. Concomitant use with MAO inhibitors. Severe renal impairment (creatinine clearance <30 m L/min) or electrolyte depletion due to hydrochlorothiazide. Concurrent lithium therapy (risk of lithium toxicity).
Avoid high-sodium foods to reduce blood pressure; limit alcohol consumption. Avoid excessive intake of tyramine-rich foods (e.g., aged cheeses, cured meats, fermented foods) as reserpine may potentiate pressor response; however, risk is low with reserpine compared to MAOIs. Maintain potassium-rich diet if hypokalemia risk exists (e.g., bananas, oranges, spinach).
Avoid potassium supplements or salt substitutes containing potassium without consulting doctor. Limit alcohol intake. Avoid excessive grapefruit juice. Maintain adequate potassium intake through diet to prevent hypokalemia.
Reserpine crosses the placenta. First trimester: limited human data but animal studies suggest risk; consider alternative if possible. Second/third trimester: may cause neonatal respiratory depression, bradycardia, hypothermia, and nasal congestion. Avoid in preeclampsia due to risk of placental hypoperfusion. Risk category C.
Hydrochlorothiazide (HCTZ) is Pregnancy Category B in first trimester and Category D in second/third trimesters. Methyldopa (M) is Category B. HCTZ use in second/third trimester may cause fetal/neonatal effects including electrolyte disturbances, jaundice, thrombocytopenia, and possible fetal growth restriction. Methyldopa has not shown teratogenicity. Aldoril D50 (M 500mg/HCTZ 50mg) is not recommended during pregnancy, especially after first trimester.
Reserpine is excreted into breast milk. M/P ratio approximately 1.6. Potential for infant bradycardia, nasal congestion, and lethargy. Contraindicated in nursing mothers due to risks.
Both methyldopa and HCTZ are excreted in breast milk. Methyldopa M/P ratio approximately 1.0; HCTZ M/P ratio variable, small amounts. Use during breastfeeding may suppress lactation due to HCTZ diuretic effect. Monitor infant for signs of hypotension, electrolyte imbalance. Caution recommended; use only if clearly needed.
No specific dose adjustments based on pharmacokinetic changes in pregnancy. Use lowest effective dose to minimize fetal risk.
Pregnancy-induced increase in plasma volume may reduce effectiveness of HCTZ, requiring dose adjustment. Methyldopa pharmacokinetics not significantly altered; however, increased clearance in pregnancy may require higher doses. In preeclampsia, dose adjustments may be needed. Avoid HCTZ in pregnancy if possible.
Hydro-Reserp combines hydrochlorothiazide and reserpine; reserpine depletes catecholamines, which may cause depression and sedation. Monitor for orthostatic hypotension and electrolyte imbalances. Avoid in patients with history of depression or peptic ulcer disease. Use with caution in patients with renal impairment.
ALDORIL D50 combines methyldopa and hydrochlorothiazide. Monitor for orthostatic hypotension, especially in volume-depleted patients. May cause positive Coombs test, hemolytic anemia, and lupus-like syndrome. Avoid in pheochromocytoma. Use caution in hepatic disease.
Take this medication exactly as prescribed; do not stop abruptly.,May cause drowsiness or dizziness; avoid driving or operating machinery if affected.,Stand up slowly from sitting or lying down to prevent falls.,Report any signs of depression, unusual mood changes, or slow heartbeat.,Avoid excessive sun exposure; may increase sensitivity to sunlight.,Do not use alcohol while taking this medication.,Monitor blood pressure regularly and keep follow-up appointments.
Take exactly as prescribed; do not skip doses or double up.,May cause dizziness or drowsiness; avoid driving until you know how it affects you.,Report unexplained fever, jaundice, or dark urine immediately.,Avoid sudden discontinuation; may cause rapid increase in blood pressure.,Stay hydrated but do not overhydrate; monitor for signs of electrolyte imbalance.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HYDRO-RESERP vs ALDORIL D50, answered by our medical review team.
HYDRO-RESERP is a Antihypertensive Combination that works by Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing reabsorption of sodium and chloride and promoting diuresis. Reserpine is a Rauwolfia alkaloid that depletes catecholamines (norepinephrine, dopamine, serotonin) from adrenergic nerve endings and brain, leading to reduced sympathetic outflow and vasodilation.. ALDORIL D50 is a Antihypertensive Combination that works by Aldoril D50 is a combination of methyldopa and hydrochlorothiazide. Methyldopa is a centrally-acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume and further lowering blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HYDRO-RESERP and ALDORIL D50 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HYDRO-RESERP is: HYDRO-RESERP contains hydrochlorothiazide (HCTZ) and reserpine. HCTZ: 25-100 mg daily orally; reserpine: 0.125-0.25 mg daily orally. Administer once daily unless intolerable hypotension; then split doses. Avoid doses exceeding HCTZ 100 mg/day and reserpine 0.25 mg/day.. The standard adult dose of ALDORIL D50 is: 1 tablet (hydrochlorothiazide 25 mg + methyldopa 250 mg) orally twice daily; maximum dose: 2 tablets (50 mg + 500 mg) twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HYDRO-RESERP and ALDORIL D50 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HYDRO-RESERP is classified as Category C. Reserpine crosses the placenta. First trimester: limited human data but animal studies suggest risk; consider alternative if possible. Second/third trimester: may cause neonatal re. ALDORIL D50 is classified as Category C. Hydrochlorothiazide (HCTZ) is Pregnancy Category B in first trimester and Category D in second/third trimesters. Methyldopa (M) is Category B. HCTZ use in second/third trimester ma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.